Cargando…

Site-Specific Considerations on Engineered T Cells for Malignant Gliomas

Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric a...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmadany, Nirmeen, Alhalabi, Obada T., Platten, Michael, Bunse, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312945/
https://www.ncbi.nlm.nih.gov/pubmed/35885047
http://dx.doi.org/10.3390/biomedicines10071738
_version_ 1784753957608882176
author Elmadany, Nirmeen
Alhalabi, Obada T.
Platten, Michael
Bunse, Lukas
author_facet Elmadany, Nirmeen
Alhalabi, Obada T.
Platten, Michael
Bunse, Lukas
author_sort Elmadany, Nirmeen
collection PubMed
description Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric antigen receptors (CAR) T cell therapy, which demonstrated promising clinical responses in other solid tumors. Current pre-clinical and interventional clinical studies suggest improved efficacy when CAR-T cells are delivered locoregionally, rather than intravenously. In this review, we summarize possible CAR-T cell administration routes including locoregional therapy, systemic administration with and without focused ultrasound, direct intra-arterial drug delivery and nanoparticle-enhanced delivery in glioma. Moreover, we discuss published as well as ongoing and planned clinical trials involving CAR-T cell therapy in malignant glioma. With increasing neoadjuvant and/or adjuvant combinatorial immunotherapeutic concepts and modalities with specific modes of action for malignant glioma, selection of administration routes becomes increasingly important.
format Online
Article
Text
id pubmed-9312945
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93129452022-07-26 Site-Specific Considerations on Engineered T Cells for Malignant Gliomas Elmadany, Nirmeen Alhalabi, Obada T. Platten, Michael Bunse, Lukas Biomedicines Review Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric antigen receptors (CAR) T cell therapy, which demonstrated promising clinical responses in other solid tumors. Current pre-clinical and interventional clinical studies suggest improved efficacy when CAR-T cells are delivered locoregionally, rather than intravenously. In this review, we summarize possible CAR-T cell administration routes including locoregional therapy, systemic administration with and without focused ultrasound, direct intra-arterial drug delivery and nanoparticle-enhanced delivery in glioma. Moreover, we discuss published as well as ongoing and planned clinical trials involving CAR-T cell therapy in malignant glioma. With increasing neoadjuvant and/or adjuvant combinatorial immunotherapeutic concepts and modalities with specific modes of action for malignant glioma, selection of administration routes becomes increasingly important. MDPI 2022-07-19 /pmc/articles/PMC9312945/ /pubmed/35885047 http://dx.doi.org/10.3390/biomedicines10071738 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Elmadany, Nirmeen
Alhalabi, Obada T.
Platten, Michael
Bunse, Lukas
Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
title Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
title_full Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
title_fullStr Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
title_full_unstemmed Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
title_short Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
title_sort site-specific considerations on engineered t cells for malignant gliomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312945/
https://www.ncbi.nlm.nih.gov/pubmed/35885047
http://dx.doi.org/10.3390/biomedicines10071738
work_keys_str_mv AT elmadanynirmeen sitespecificconsiderationsonengineeredtcellsformalignantgliomas
AT alhalabiobadat sitespecificconsiderationsonengineeredtcellsformalignantgliomas
AT plattenmichael sitespecificconsiderationsonengineeredtcellsformalignantgliomas
AT bunselukas sitespecificconsiderationsonengineeredtcellsformalignantgliomas